Effect of very-low–dose niacin on high-density lipoprotein in patients undergoing long-term statin therapy
- 1 March 2002
- journal article
- clinical trial
- Published by Elsevier in American Heart Journal
- Vol. 143 (3) , 514-518
- https://doi.org/10.1067/mhj.2002.120158
Abstract
No abstract availableKeywords
This publication has 27 references indexed in Scilit:
- Gemfibrozil for the Secondary Prevention of Coronary Heart Disease in Men with Low Levels of High-Density Lipoprotein CholesterolNew England Journal of Medicine, 1999
- “Isolated” Low High-Density Lipoprotein CholesterolAnnals of Pharmacotherapy, 1997
- Distribution of lipids in 8,500 men with coronary artery diseaseThe American Journal of Cardiology, 1995
- Familial lipoprotein disorders in patients with premature coronary artery disease.Circulation, 1992
- Decreased HDL2 and HDL3 cholesterol, Apo A-I and Apo A-II, and increased risk of myocardial infarction.Circulation, 1992
- National Cholesterol Education Program's recommendations, and implications of “missing” high-density lipoprotein cholesterol in cardiac rehabilitation programsThe American Journal of Cardiology, 1991
- High-density lipoprotein cholesterol and cardiovascular disease. Four prospective American studies.Circulation, 1989
- Helsinki Heart Study: Primary-Prevention Trial with Gemfibrozil in Middle-Aged Men with DyslipidemiaNew England Journal of Medicine, 1987
- Fifteen year mortality in Coronary Drug Project patients: Long-term benefit with niacinJournal of the American College of Cardiology, 1986
- The Lipid Research Clinics Coronary Primary Prevention Trial ResultsJAMA, 1984